tiprankstipranks
Crinetics Pharma (CRNX)
NASDAQ:CRNX
US Market
CRNX
Crinetics Pharmaceuticals
RESEARCH TOOLSreports
Want to see CRNX full AI Analyst Report?

Crinetics Pharmaceuticals (CRNX) Ratios

783 Followers

Crinetics Pharmaceuticals Ratios

CRNX's free cash flow for Q1 2026 was $0.98. For the 2026 fiscal year, CRNX's free cash flow was decreased by $ and operating cash flow was $-13.08. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 18.60 12.32 23.04 13.07 12.45
Quick Ratio
 18.56 12.30 23.04 13.07 12.45
Cash Ratio
 1.61 1.19 4.43 1.25 1.18
Solvency Ratio
 -4.08 -3.22 -2.69 -2.22 -4.55
Operating Cash Flow Ratio
 -5.83 -4.44 -3.79 -3.78 -4.16
Short-Term Operating Cash Flow Coverage
 -63.37 -58.24 0.00 -39.85 -109.61
Net Current Asset Value
$ 1.20B$ 904.93M$ 1.27B$ 477.91M$ 309.34M
Leverage Ratios
Debt-to-Assets Ratio
 0.03 0.04 0.04 0.08 <0.01
Debt-to-Equity Ratio
 0.04 0.05 0.04 0.10 <0.01
Debt-to-Capital Ratio
 0.04 0.05 0.04 0.09 <0.01
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 1.09 1.14 1.08 1.18 1.11
Debt Service Coverage Ratio
 -82.89 -79.07 0.00 -53.08 -158.80
Interest Coverage Ratio
 0.00 0.00 0.00 0.00 0.00
Debt to Market Cap
 <0.01 <0.01 0.00 <0.01 <0.01
Interest Debt Per Share
 0.46 0.52 0.64 0.89 0.06
Net Debt to EBITDA
 0.12 0.10 0.63 0.01 0.18
Profitability Margins
Gross Profit Margin
98.89%86.02%100.00%100.00%100.00%
EBIT Margin
-3020.32%-6714.77%-32613.47%-5547.17%-3544.06%
EBITDA Margin
-2997.49%-6664.23%-32345.43%-5519.81%-3523.31%
Operating Profit Margin
-3020.32%-6714.77%-32613.47%-5547.17%-3544.06%
Pretax Profit Margin
-2746.18%-6043.88%-28720.69%-5345.85%-3460.38%
Net Profit Margin
-2747.18%-6046.22%-28720.69%-5345.85%-3460.38%
Continuous Operations Profit Margin
-2747.18%-6046.22%-28720.69%-5345.85%-3460.38%
Net Income Per EBT
100.04%100.04%100.00%100.00%100.00%
EBT Per EBIT
90.92%90.01%88.06%96.37%97.64%
Return on Assets (ROA)
-35.42%-40.98%-20.80%-33.77%-46.54%
Return on Equity (ROE)
-43.96%-46.90%-22.52%-39.79%-51.82%
Return on Capital Employed (ROCE)
-41.03%-49.20%-24.65%-37.64%-51.74%
Return on Invested Capital (ROIC)
-40.83%-48.89%-24.52%-37.38%-51.58%
Return on Tangible Assets
-35.42%-40.98%-20.80%-33.77%-46.54%
Earnings Yield
-13.41%-10.63%-7.22%-10.38%-17.23%
Efficiency Ratios
Receivables Turnover
 3.18 13.00 0.12 0.43 1.95
Payables Turnover
 0.02 0.05 0.00 0.00 0.00
Inventory Turnover
 0.07 0.53 0.00 0.00 0.00
Fixed Asset Turnover
 0.34 0.14 0.02 0.07 0.95
Asset Turnover
 0.01 <0.01 <0.01 <0.01 0.01
Working Capital Turnover Ratio
 0.02 <0.01 <0.01 <0.01 0.01
Cash Conversion Cycle
 -17.80K -6.96K 2.98K 850.51 186.85
Days of Sales Outstanding
 114.80 28.08 2.98K 850.51 186.85
Days of Inventory Outstanding
 5.59K 685.90 0.00 0.00 0.00
Days of Payables Outstanding
 23.50K 7.67K 0.00 0.00 0.00
Operating Cycle
 5.71K 713.98 2.98K 850.51 186.85
Cash Flow Ratios
Operating Cash Flow Per Share
 -3.98 -4.02 -2.80 -2.86 -2.22
Free Cash Flow Per Share
 -4.03 -4.08 -2.84 -2.94 -2.25
CapEx Per Share
 0.05 0.06 0.05 0.08 0.03
Free Cash Flow to Operating Cash Flow
 1.01 1.02 1.02 1.03 1.01
Dividend Paid and CapEx Coverage Ratio
 -77.52 -65.59 -58.79 -35.48 -69.57
Capital Expenditure Coverage Ratio
 -77.52 -65.59 -58.79 -35.48 -69.57
Operating Cash Flow Coverage Ratio
 -8.65 -7.79 -4.37 -3.22 -37.47
Operating Cash Flow to Sales Ratio
 -22.92 -49.11 -217.49 -41.44 -24.32
Free Cash Flow Yield
-11.19%-8.76%-5.56%-8.28%-12.28%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -7.24 -9.41 -13.84 -9.63 -5.80
Price-to-Sales (P/S) Ratio
 201.44 568.91 3.98K 514.87 200.82
Price-to-Book (P/B) Ratio
 2.81 4.41 3.12 3.83 3.01
Price-to-Free Cash Flow (P/FCF) Ratio
 -8.68 -11.41 -17.97 -12.08 -8.14
Price-to-Operating Cash Flow Ratio
 -8.68 -11.59 -18.28 -12.42 -8.26
Price-to-Earnings Growth (PEG) Ratio
 0.26 -0.28 0.00 -0.56 -0.46
Price-to-Fair Value
 2.81 4.41 3.12 3.83 3.01
Enterprise Value Multiple
 -6.60 -8.43 -11.66 -9.31 -5.52
Enterprise Value
 3.68B 4.33B 3.92B 2.06B 921.67M
EV to EBITDA
 -6.80 -8.43 -11.66 -9.31 -5.52
EV to Sales
 203.77 562.03 3.77K 514.08 194.57
EV to Free Cash Flow
 -8.78 -11.27 -17.05 -12.06 -7.89
EV to Operating Cash Flow
 -8.89 -11.45 -17.34 -12.40 -8.00
Tangible Book Value Per Share
 12.30 10.55 16.40 9.28 6.09
Shareholders’ Equity Per Share
 12.30 10.55 16.40 9.28 6.09
Tax and Other Ratios
Effective Tax Rate
 >-0.01 >-0.01 0.00 0.00 0.00
Revenue Per Share
 0.17 0.08 0.01 0.07 0.09
Net Income Per Share
 -4.77 -4.95 -3.69 -3.69 -3.15
Tax Burden
 1.00 1.00 1.00 1.00 1.00
Interest Burden
 0.91 0.90 0.88 0.96 0.98
Research & Development to Revenue
 19.70 43.15 231.14 42.00 27.49
SG&A to Revenue
 11.44 24.86 95.99 14.48 8.95
Stock-Based Compensation to Revenue
 5.55 11.83 66.78 10.20 5.97
Income Quality
 0.83 0.81 0.76 0.78 0.70
Currency in USD